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ABSTRACT: 
Vertebrate DNA crosslink repair excises toxic replication-blocking DNA crosslinks. 
Numerous factors involved in crosslink repair have been identified, and mutations in their 
corresponding genes cause Fanconi anemia (FA). A key step in crosslink repair is 
monoubiquitination of the FANCD2–FANCI heterodimer, which then recruits nucleases to 
remove the DNA lesion. Here, we use cryoEM to determine the structure of recombinant 
chicken FANCD2 and FANCI complexes. FANCD2–FANCI adopts a closed conformation 
when the FANCD2 subunit is monoubiquitinated, creating a channel that encloses double-
stranded DNA. Ubiquitin is positioned at the interface of FANCD2 and FANCI, and acts as a 
covalent molecular pin to trap the complex on DNA. In contrast, isolated FANCD2 is a 
homodimer unable to bind DNA, suggestive of an autoinhibitory mechanism that prevents 
premature activation. Together, our work suggests that FANCD2–FANCI is a clamp that is 
locked onto DNA by ubiquitin, with distinct interfaces that may recruit other DNA repair 
factors.  
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INTRODUCTION 
Vertebrates repair DNA interstrand crosslinks through a complex and essential 
process1. Genetic inactivation of crosslink repair in humans results in Fanconi anemia (FA), a 
disorder characterized by abnormal development, loss of blood production, and marked 
cancer susceptibility2. Remarkably, autosomal recessive mutations in any one of 20 genes 
(FANCA to FANCQ) result in this genetic illness, and collectively the FANC gene products 
function in a FA DNA crosslink repair pathway3. An understanding of this pathway is 
emerging from cell biological and biochemical reconstitution studies4-9. These indicate that a 
number of the FANC gene products form a large nuclear E3 monoubiquitin ligase complex 
(the FA core complex). When DNA replication is stalled, the FA core complex is activated to 
monoubiquitinate the FANCD2–FANCI heterodimer (ubD2–I)6,7,10-12. Activated ubD2–I 
localizes to sites of DNA damage and is thought to recruit a nuclease incision complex, 
consisting of FANCP (SLX4) and FANCQ (XPF)–ERCC1, to remove the crosslinked 
DNA13-20. Genetic studies also indicate that reversal of the monoubiquitination step by the 
deubiquitinating enzyme USP1, in complex with UAF1, is required to complete DNA 
crosslink repair21-23.  
Most cases of FA are due to mutations in components of the FA core complex, 
impairing its activity and resulting in a failure to monoubiquitinate FANCD224. Loss of 
FANCI also abolishes FANCD2 modification11,12. Monoubiquitination is a tightly controlled 
process, and is regulated by phosphorylation11,12,25-27. Altogether this suggests that 
heterodimerization of FANCD2 with FANCI is essential for this key step in the pathway.  
Monoubiquitination of FANCD2 can be recapitulated in cell free systems in the 
presence of DNA8,9,28,29. Many different DNA substrates stimulate the reaction to a similar 
extent despite a modest preference of D2–I for forked or crosslinked DNA structures in DNA 
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binding assays30,31. FANCI is not substantially monoubiquitinated by purified chicken FA 
core complexes8,29 and is only inefficiently monoubiquitinated by a human complex in vitro9. 
DNA crosslink repair in cells can be largely rescued by a FANCI variant with a mutated 
monoubiquitination site, suggesting that FANCI ubiquitination is not essential25. Together, 
both in vitro and in vivo data suggest that monoubiquitination of FANCD2 (not FANCI) is 
the critical and predominant function of the FA core complex.  
An x-ray crystal structure of the FANCD2–FANCI dimer revealed that the 
monoubiquitination sites, as well as regulatory FANCI phosphorylation sites, map to the 
dimerization interface, and that FANCI harbors a binding-site for DNA31. Still, a 
longstanding mystery is why D2–I monoubiquitination and its subsequent reversal are so 
fundamental for crosslink repair. Moreover, the mechanistic details of FANCD2 and FANCI 
interaction with DNA, and how ubD2–I might ultimately enable DNA crosslink removal are 
not known. 
Here, we expressed and purified Gallus gallus FANCD2 and FANCI complexes, and, 
using a recombinant FA core complex, we obtained monoubiquitinated D2–I. Using cryoEM 
and biochemical assays, we delineated details of how these factors interact with DNA. We 
determined the structure of ubD2–I, which we show adopts a tight clamp on DNA. We also 
find that FANCD2 itself forms a homodimer that is unable to interact with DNA, but this can 
interchange with FANCI, to create a D2–I heterodimer that interacts with DNA.  Our finding 
that the D2–I dimer transforms into a locked DNA clamp upon monoubiquitination of 
FANCD2 provides insight into how crosslink repair could be initiated. 
RESULTS 
CryoEM structure of unmodified D2–I 
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First, we purified a recombinant D2–I complex after co-expression of both proteins in 
insect cells (Extended Data Fig. 1a). The purified complex functions as a monoubiquitination 
substrate in vitro (Fig. 1a,b) and interacts with DNA (see below). We used cryoEM to 
investigate the architecture of unmodified D2–I in the presence of bound DNA, and obtained 
a 3D structure at an overall resolution of ~4.1 Å (Fig. 1c, d; Extended Data Fig. 1b-e; Table 
1). We then built homology models of FANCD2 and FANCI, and fitted these into the map 
(Extended Data Fig. 2a-c). The structure of chicken D2–I is highly similar to the previously-
reported crystal structure of the Mus musculus proteins31, in agreement with the high degree 
of structural and functional conservation of the FA pathway across vertebrates (Extended 
Data Fig. 2d, Supplementary Table 1; Supplementary Notes 1 and 2). Although the cryoEM 
sample was prepared in the presence of DNA, DNA was not visible in the maps, consistent 
with a fast off-rate. 
As previously reported31, the FANCD2 and FANCI proteins share a striking structural 
similarity containing a series of ɑ-helices arranged into four superhelical ɑ-solenoid 
structures (S1–S4) and two helical domains (HD1, HD2). They fold into an overall shape 
akin to two antiparallel saxophones. In this arrangement, the ubiquitination sites (D2K563 and 
IK525 for the chicken proteins) are buried within the dimerization interface, indicating that 
remodeling of the complex is very likely required for access by the FA monoubiquitin ligase 
complex. In the cryoEM structure, the C-terminal domain of FANCD2 was at a lower 
resolution due to flexibility of this region (Fig. 1d). Flexibility of the C-terminal domains was 
also observed in a previous negative-stain EM study32. 
CryoEM of ubD2–I reveals that it is a DNA clamp 
Next, to purify a monoubiquitinated complex, we incubated D2–I with His-tagged 
ubiquitin, E1, E2 (UBE2T), recombinant FA core complex29 and DNA (Fig. 1a). We used a 
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double-stalled fork DNA, but other DNA structures are also effective in stimulating 
monoubiquitination8,28. FANCD2 was specifically monoubiquitinated on K563, but FANCI 
was not ubiquitinated, as previously observed29. We enriched for the ubiquitinated complex 
by affinity chromatography using the His-tag on ubiquitin (Fig. 1b). Using cryoEM, we 
obtained a 3D structure of ubD2–I at an overall resolution of ~3.8 Å (Fig. 1c, d; Extended 
Data Fig. 1b-e; Table 1), allowing us to build models for FANCD2, FANCI and ubiquitin 
(Fig. 2a; Extended Data Fig. 2).  
The structure of ubD2–I is markedly different from the unmodified complex. Symmetry 
was not obvious in 2D class averages (Fig. 1c), but the 3D reconstruction showed that the 
overall ubD2–I complex retains some pseudo-symmetric features (Fig. 1d). In the 
monoubiquitinated form, FANCD2 and FANCI are folded towards each other so the C-
terminal domains of each monomer (akin to the bells of the saxophone), wrap around density 
that we assigned to double-stranded DNA (see below). In agreement with subunit flexibility 
and remodeling of the complex, multi-body refinement of ubD2–I showed that there is 
variability in the relative positions of FANCD2 and FANCI (Supplementary Video 1).  
DNA binding exposes the FANCD2K563 monoubiquitination site at the dimer interface 
Superimposition of the D2–I and ubD2–I models showed that the dimer interface acts 
as a hinge, allowing the C-termini of FANCD2 and FANCI to swing towards each other, 
rotating by almost 70° in the monoubiquitinated complex (Supplementary Videos 2-4). This 
is largely a rigid body movement of both subunits, but the N- and C-terminal regions of 
FANCD2 are also remodeled (Fig. 1d; Extended Data Fig. 2d). This conformational change 
opens a cleft to expose the K563 monoubiquitination site in FANCD2 on the backside of the 
hinge, where we unambiguously identified density for ubiquitin in the cryoEM map (Fig. 1d; 
Extended Data Fig. 2b). Ubiquitin is covalently anchored onto FANCD2 (Fig. 1b) but it 
 7 
docks onto the surface of FANCI via the hydrophobic Ile44 patch on ubiquitin, and likely 
stabilizes the complex (Fig. 2a-b). Crosslinking mass spectrometry also showed that ubiquitin 
is in close proximity to both FANCD2 and FANCI (Fig. 2c-e; Extended Data Fig. 3a; 
Supplementary Table 2).  
In contrast, the FANCI monoubiquitination site (K525) is only partially exposed 
because the cleft where it is located remains closed (Fig. 2e), explaining why it is 
inefficiently monoubiquitinated with recombinant or native FA core complex in vitro8,9,29 
(Fig. 1b). In cells, FANCI monoubiquitination is stimulated by phosphorylation (which may 
further open up the dimerization interface31) but it is not essential for DNA crosslink 
repair12,25.  
The C-terminal domains of FANCD2 and FANCI form a channel to embrace DNA 
The C-terminal solenoids (S4) of FANCD2 and FANCI, as well as additional 
unmodeled C-terminal regions, mediate contacts at the new interface (Fig. 3a,b). These 
interactions likely stabilize the C-terminal region of FANCD2, which is flexible in D2–I but 
becomes well-ordered in the ubD2–I map (Fig. 1d).  
The repositioned C-terminal domains of FANCD2 and FANCI in the mono-
ubiquitinated complex form a new channel between the two protomers. In agreement with an 
important role for the C-terminal domain of FANCD2, deletion of residues 1147–1451 in the 
human protein results in loss of FANCD2 monoubiquitination in vitro and in cells, loss of in 
vitro DNA binding, and disruption of crosslink repair33. The channel contained density for 
~15–20 bp double-stranded DNA (Fig. 1d). The DNA extends beyond the channel and we 
could model a total of 33 bp (Fig. 3c). The DNA was at lower resolution than the rest of the 
map, likely because of heterogeneity in the DNA position, and inherent flexibility. DNA 
makes contacts with both proteins, but it appears to be shifted towards FANCI, adopting a 
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binding mode similar to that in a previously reported low-resolution FANCI–DNA crystal 
structure31. Contacts are likely mediated largely through interactions between the negatively-
charged phosphate backbone and positively-charged surface residues31. Intriguingly, the 
bound DNA is kinked next to the C-terminal domains within the ubD2–I complex (Fig. 3c).  
Ubiquitin is a covalent molecular pin that locks the ubD2–I clamp on DNA  
D2–I interacts with DNA31,33 and DNA is required for monoubiquitination of D2–I in 
vitro8,28, but the role of DNA in this reaction was unclear. Our data suggested that DNA 
binding is required to close the D2–I clamp and expose the monoubiquitination site. To 
further investigate this, we performed monoubiquitination assays of D2–I in the presence of a 
series of double-stranded DNAs of varying lengths. We used linear double-stranded DNA 
since this allowed us to specifically analyze the length dependence. D2–I was 
monoubiquitinated in the presence of a 19 bp DNA, but not with a 14 bp DNA (Extended 
Data Fig. 3b). We also analyzed protein–DNA interactions within these reactions by loading 
the monoubiquitination assays performed in the presence of different DNAs directly onto 
native gels for analysis by electrophoretic mobility shift assays (EMSAs). D2–I did not bind 
to a 14 bp DNA, but interacted efficiently with DNA substrates that were 19 bp or longer 
(Extended Data Fig. 3b). Therefore, these biochemical data show that the minimum DNA 
length required for ubiquitination (15–19 bp) correlates with the minimum length required for 
D2–I binding. This length also agrees well with the length of DNA encircled by ubD2–I in 
the cryoEM structure.  
Together, our structures and biochemical studies explain why and how DNA stimulates 
FANCD2 monoubiquitination: D2–I binds double-stranded DNA, promoting closure of the 
heterodimer to expose the K563 monoubiquitination site in FANCD2 and allow access to the 
activated E2 enzyme. We also hypothesized that monoubiquitination of FANCD2 on the 
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backside of the hinge acts as a covalent molecular pin, locking the closed heterodimer on 
DNA and preventing it from rotating back to the open D2–I conformation. In agreement with 
this, monoubiquitination results in a small, but reproducible, increase in DNA binding 
affinity, possibly due to a slower off-rate (Extended Data Fig. 3c).  
To test whether ubiquitin slows the off-rate and locks the complex on DNA, we 
performed two-color DNA displacement assays: we incubated D2–I with FAM-labeled DNA 
and then tested the ability of a second (Alexa-labeled) DNA to be incorporated into D2–I by 
displacing the FAM-DNA. We found that in the absence of ubiquitination, the second DNA 
is readily incorporated into D2–I (Fig. 4). In contrast, when FAM-DNA is used to form the 
ubD2–I complex, a much smaller amount of the competing DNA is incorporated (Fig. 4). 
Together, these experiments provide evidence that ubiquitin locks the D2–I complex on 
DNA, effectively slowing the off-rate. 
Isolated FANCD2 forms a closed, auto-inhibited homodimer 
A major remaining question was why FANCD2 was not monoubiquitinated in vivo or 
in vitro in the absence of FANCI8,16,28. To address this, we purified FANCD2 and FANCI 
separately. Purified FANCI ran as a monomer on gel filtration chromatography whereas, 
unexpectedly, FANCD2 ran as a dimer (Fig. 5a; Extended Data Fig. 4a). Interestingly, a 
recent study showed that purified human FANCD2 also runs as a species of larger size 
compared to human FANCI, likely corresponding to a dimeric FANCD234.  
Next, we assessed the DNA binding capacities of each protein and found that FANCI 
bound DNA efficiently but FANCD2 did not interact with DNA at any of the concentrations 
we tested (Fig. 5b; Extended Data Fig. 4b-c). Moreover, isolated FANCD2 was not 
substantially monoubiquitinated by the FA core complex, and this could not be stimulated by 
DNA (Extended Data Fig. 5a).  
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To understand the molecular basis of FANCD2 dimerization and gain insight into why 
it did not bind DNA, we determined the structure of the FANCD2 homodimer using cryoEM 
to ~3.4 Å resolution (Fig. 5c-e; Extended Data Fig. 1; Extended Data Fig. 2a, c). The 
FANCD2 dimer was symmetric, with each protomer containing the same overall domain 
architecture as in the heterodimeric complex. Surprisingly, the FANCD2 homodimer was in a 
closed conformation, more similar to ubD2–I than to D2–I. This provides a molecular 
explanation for the lack of DNA binding by isolated FANCD2: The DNA binding sites were 
blocked because it was in a closed conformation that presumably does not open to allow 
entry of a double-stranded helix. In addition, FANCD2 homodimerization occludes K563 on 
both protomers, likely preventing their ubiquitination (Fig. 5e). 
The FANCD2 homodimer was stable over a gel filtration column, indicative of a high 
affinity interaction. To investigate how the heterodimeric D2–I complex forms, we mixed 
purified FANCD2 and FANCI and analyzed their oligomerization state. We found that after 
incubation with FANCD2, the migration position of FANCI on a gel filtration column shifted 
to the position of a dimer (Fig. 5a; Extended Data Fig 4a). This suggested that the monomeric 
FANCI displaced one of the FANCD2 protomers in the homodimer. To definitively address 
this, we immobilized FANCD2 on Streptavidin resin and incubated it with untagged FANCI. 
After washing, FANCI was bound to the beads in approximately 1:1 stoichiometric ratio with 
FANCD2 (Extended Data Fig. 5b). This is consistent with FANCI displacing one of the 
FANCD2 protomers to form the D2–I complex.  
DISCUSSION 
Until now, the precise role of DNA in monoubiquitination of FANCD2 was unknown. 
It had also remained unclear how the monoubiquitinated lysine on FANCD2 was accessed by 
UBE2T and the FA core complex, since it was occluded at the interface of FANCD2 and 
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FANCI in a previous crystal structure31. Here, our structural and biochemical analyses of 
FANCD2 and FANCI allow us to propose a new model for how DNA crosslink repair is 
initiated (Fig. 5f): D2–I binds DNA at stalled replication forks, and this causes a hinge-like 
rotation of FANCD2 and FANCI so they encircle double-stranded DNA (Fig. 5f). Transition 
into this closed conformation exposes a region on the back of the FANCD2 hinge, allowing 
the FA core complex and UBE2T to access the monoubiquitination site. Ubiquitin then acts 
as a covalent molecular pin to lock the ubD2–I DNA clamp into the closed conformation. We 
are not aware of any other examples where covalently-linked ubiquitin locks a new protein 
conformation. Thus, our analysis uncovers a new function for ubiquitination. 
Unexpectedly, we find that recombinant FANCD2 alone purifies as a homodimer. A 
recent study showed that purified human FANCD2 migrates as a larger species than human 
FANCI on a gel filtration column, consistent with human FANCD2 also forming a 
homodimeric complex34. Here, we show that the FANCD2 homodimer adopts a closed 
conformation that is unable to engage DNA. It cannot be ubiquitinated because the 
monoubiquitinated lysines are occluded at the dimer interface. Upon incubation with FANCI, 
the FANCD2 homodimer readily exchanges into a stable D2–I heterodimer, and adopts an 
open conformation, permissive for DNA binding. Thus, our results suggest a mechanism of 
autoinhibition wherein isolated FANCD2 cannot be prematurely recruited to DNA and 
cannot be monoubiquitinated prior to assembly with FANCI. Since the D2–I heterodimer is 
favored over the FANCD2 homodimer, it is unlikely that there would be substantial amounts 
of monomeric FANCI and homodimeric FANCD2 in the cell. However, it remains possible 
that the dynamics of D2–I association may be modulated by post-translational modifications. 
In the physiological context, it is not known if FANCD2 homodimers act in a 
regulatory capacity to control the amount of D2–I complex in the cell, or if homodimerization 
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is simply a mechanism to sequester any excess FANCD2 if there is an imbalance in the ratio 
of FANCD2:FANCI proteins produced. Nevertheless, when endogenous FANCD2 is purified 
from cells, it does not come down with equivalent levels of FANCI12,35. It is therefore 
possible that the FANCD2–FANCI interaction may be regulated and that a fraction of 
endogenous FANCD2 is not heterodimerized with FANCI, in agreement with previous 
data35. FANCI may have additional functions to those shared with FANCD2 in DNA repair, 
supporting the hypothesis that the proteins might exist as distinct entities36,37. Future 
experiments will be required to test whether FANCD2 homodimerization regulates the FA 
pathway. 
In monoubiquitination assays, both chicken, human and murine D2–I heterodimers 
show little selective preference for different forms of double-stranded DNA8,9,28,31,38, 
although DNA binding assays show a modest preference for certain DNA structures31,33. 
Thus, it is unclear whether the D2–I dimers are specifically recruited by replication fork 
structures, crosslinked DNA, the stalled replisome, or other factors. Since the FA pathway 
plays a more general role in response to stalled replication forks, D2–I is likely to bind a 
protein or DNA structure common to all pathways. We now show that the ubD2–I dimer 
locks into a clamp around double-stranded DNA with a footprint of ~20 nt. Repair of a DNA 
crosslink in a Xenopus cell-free system showed that there is a careful choreography of events 
that occur after two replication forks converge on a crosslink10,39. The forks stall at a distance 
of 20–40 nt from the crosslink, and subsequently, one fork advances until it reaches the 
nucleotide preceding the crosslink. At this point the FANCP–FANCQ nuclease complex cuts 
around the crosslink (unhooking) on one strand, and this step is abolished when D2–I is 
depleted10,14,15,40.  
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We suggest a model whereby D2–I is primed to interact with DNA, possibly when a 
stalled replication fork is ~20 nt from the crosslink. This could signal to the FA core complex 
to monoubiquitinate D2–I, locking it around DNA just adjacent to the crosslink site. ubD2–I 
kinks the double-stranded DNA helix, possibly providing distortion that marks the 
crosslinked DNA substrate for the nuclease incision complex. Importantly, the ubiquitination 
of FANCD2 alone is sufficient to lock the D2–I dimer on DNA, consistent with genetic 
evidence that FANCI monoubiquitination is not required for crosslink repair12. ubD2–I is 
thought to directly recruit the incision complex10,18, but curiously, the Ile44 patch of ubiquitin 
that interacts with ubiquitin-binding domains is buried at the interface of ubiquitin and 
FANCI (Fig. 2b). The covalently-linked ubiquitin could swing out to expose the Ile44 patch, 
allowing recognition of ubiquitin, or alternatively, the incision complex may recognize an 
alternate solvent-exposed interface on ubD2–I. Future studies will aim to test these models.   
Finally, our work provides an explanation for why it is essential to de-ubiquitinate 
FANCD2 for the completion of crosslink repair. Genetic evidence in chicken DT40 cells and 
in mice indicated that knockouts of USP1 lead to the persistence of ubiquitinated FANCD2 
tethered to chromatin21,41. This aborts crosslink repair. Since ubiquitin locks the ubD2–I 
clamp on DNA, ubiquitin must be removed for the clamp to open, releasing the DNA. Failure 
to carry out this step would lead to the persistence of the clamp on DNA which could 
promote uncontrolled cutting by the incision complex, prevent repair after incision, or 
possibly create a protein–DNA obstacle to transcription or replication of DNA. The structures 
of activated D2–I reported here, as well as the recent structure of the FA core complex29, set 
the stage for future work to ultimately obtain a complete biochemical and structural 
understanding of DNA interstrand crosslink repair.  
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FIGURE LEGENDS 
Fig. 1: Purification and structures of D2–I and ubD2–I. 
a Scheme for monoubiquitination of D2–I using fully recombinant components. The His-tag on 
ubiquitin is shown as a blue dashed line. b ubD2–I was enriched from the monoubiquitination mixture 
by purification of His-tagged ubiquitin on Ni-NTA. The load, unbound fraction, two wash fractions 
and elution were analyzed by Coomassie-stained SDS-PAGE (top) and Western blotting with an anti-
Ubiquitin antibody (bottom). A control reaction lacking ubiquitin is also shown. Uncropped gel and 
blot are available in Supplementary Fig. 1. These results are representative of experiments performed 
at least three  times. c Selected 2D reference-free class averages of D2–I (left) and ubD2–I (right). 
Both samples were prepared with DNA. An asterisk marks density extending from the side of the 
ubD2–I complex that we assign to DNA. d CryoEM maps of D2–I (left) and ubD2–I (right), 
segmented into FANCD2 (blue), FANCI (magenta), ubiquitin (green) and DNA (yellow). 
 
Fig. 2: Ubiquitin is anchored to K563 on FANCD2 but also contacts FANCI. 
a The ubiquitin moiety attached to FANCD2 makes extensive contacts with FANCI. b Close-up view 
of the monoubiquitination site. Ile44 (orange) of ubiquitin is shown. c Map of crosslinks identified in 
the ubD2–I complex. Crosslinking mass spectrometry revealed 122 crosslinks (1% false discovery 
rate) between residues that are in close proximity. Crosslinks are colored by Cα-Cα distance between 
linked residue pairs measured in the 3D model of ubD2–I. Two crosslinks are not compatible with the 
model but are consistent with the flexibility observed within this complex (Supplementary Video 1). 
Proteins are shown as curved bars and residues that are present in the 3D model are highlighted. d 
Crosslinks within expected distance (green) and exceeding expected distance (overlength, red) 
mapped onto the ubD2–I structure. e Details of lysines K563 in FANCD2 (left) and K525 in FANCI 
(right) within the ubD2–I structure, shown in sticks for lysines (orange), as a surface representation of 
the model for FANCD2 (blue) and FANCI (magenta), and in cartoon for ubiquitin (green). The 
residues crosslinked between ubiquitin and FANCD2 and FANCI are labeled. 
 
Fig. 3: ubD2–I is a DNA clamp. 
a Models for FANCD2 (blue), FANCI (magenta) and ubiquitin (green) built into the ubD2–I cryoEM 
map. The N- and C-termini, solenoids 1–4 (S1–S4) and helical domains (HD1, HD2)31 of FANCD2 
and FANCI are indicated. The monoubiquitinated lysine in FANCD2 and the lysine that can be 
monoubiquitinated in FANCI are shown in orange. b Close-up view of the C-terminal domains (S4) 
of ubD2–I that clamp around DNA. c Model of 33 bp double-stranded DNA (yellow) in the ubD2–I 
map. DNA is kinked within the ubD2–I complex. 
 
Fig. 4: Monoubiquitination locks the D2–I clamp onto DNA. 
A 44-bp FAM-labeled dsDNA (red) was incubated with D2–I (30 nM) or used to form ubD2–I 
complex (30 nM). Then, an Alexa-labeled DNA (green) of the same length and sequence was added 
in increasing concentrations (0–80 nM) to these complexes. Overlays of the FITC and Alexa647 
channels (top) and the Alexa647 channel alone (middle) are shown. The competing (Alexa) DNA 
readily incorporates into free D2–I (left) and FAM-DNA:D2–I (middle), but does not incorporate into 
the FAM-DNA:ubD2–I complex. The intensities of total Alexa-DNA and the fraction incorporated 
into the complex (shifted) were quantified and the percentage of shifted Alexa-DNA was plotted in 
the bottom panel. These data are representative of experiments performed two times. Uncropped gels 
are available in Supplementary Fig. 1. Data for plot is available as source data. 
 
Fig. 5: FANCI forms a monomer and binds DNA whereas FANCD2 is dimeric and does not 
bind DNA. 
 19 
a Size exclusion chromatography analysis of purified FANCI, FANCD2, D2–I, and FANCI mixed 
with FANCD2. A single asterisk (*) indicates the migration position for monomers. A double asterisk 
(**) indicates the migration position for dimers. This experiment was performed three times and a 
representative chromatogram is shown. b DNA binding of FANCD2 and D2–I was analyzed by 
EMSAs performed with 20 nM 39 bp double-stranded DNA and 0–140 nM protein. Representative 
gels of experiments independently performed three times are shown. Uncropped gels are available in 
Supplementary Fig. 1. c Selected 2D reference-free class averages of FANCD2. Scale bar is 100 Å. d 
CryoEM map of FANCD2 homodimer. The locations of the N- and C-termini are marked. e Model of 
FANCD2 dimer. The buried K563 residue (red) on FANCD2 is shown in close-up. f Model for 
regulation of FANCD2 and FANCI in DNA crosslink repair. Isolated FANCD2 purifies as a 
homodimer that is closed, does not bind DNA, and is not monoubiquitinated. Upon incubation with 
purified (monomeric) FANCI, this exchanges into a D2–I complex with an open conformation. D2–I 
binds and encircles DNA, converting the complex into a closed conformation, and thereby acting as a 
DNA clamp. The ubiquitination site on FANCD2 is exposed in the closed conformation, allowing 
access to the FA core complex and E2 enzyme. Ubiquitin locks the D2–I clamp in a closed 
conformation so it is not readily released from DNA. 
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Table 1. Cryo-EM data collection, refinement and validation statistics 
 D2–I 
(EMD-10532, 
PDB 6TNG) 
ubD2–I 
(EMD-10531, 
PDB 6TNF) 
D2 
(EMD-10534, 
PDB 6TNI) 
Data collection and processing    
Magnification 81,000 X 81,000 X 81,000 X 
Voltage (kV) 300 300 300 
Electron exposure (e–/Å2) ~70  ~70  ~70  
Defocus range (μm) -1.8 to -3.5 -1.8 to -3.5 -1.8 to -3.5 
Pixel size (Å) 1.11 (LMB) 1.06 (eBIC), 
1.11 (LMB) 
1.11 (eBIC) 
Symmetry imposed C1 C1 C2 
Initial particle images (no.)* ~2,000,000 ~2,500,000 ~3,000,000 
Final particle images (no.) 171,936 146,245 901,085 
Map resolution (Å) 4.1 3.8 3.4 
    FSC threshold 0.143 0.143 0.143 
Map resolution range (Å) 4.1 to > 10 3.8 to > 10 3.4 to > 10 
    
Refinement    
Initial model used (PDB code) 3S4W 3S4W 3S4W 
Model resolution (Å) 4.1 3.8 3.4 
    FSC threshold 0.143 0.143 0.143 
Model resolution range (Å) n/a n/a n/a 
Map sharpening B factor (Å2) -103 -77 -108  
Model composition    
    Non hydrogen atoms 8,241 10,194 11,625 
    Protein residues 2,060 2,206 2,134 
    Ligands 0 0 0 
B factors (Å2)    
    Protein not estimated not estimated not estimated 
    Ligand    
R.m.s. deviations    
    Bond lengths (Å) 0.008 0.008 0.008 
    Bond angles (°) 1.39 1.41 1.40 
    
Validation    
MolProbity score 2.25 2.19 2.81 
Clashscore 10.0 8.76 4.51 
Poor rotamers (%) 0.00 0.00 15.63 
Ramachandran plot    
    Favored (%) 80.22 81.51 84.33 
    Allowed (%) 18.94 17.83 15.19 
    Disallowed (%) 0.84 0.65 0.47 
 
* Initial number of particles after autopicking. This number includes many blank picks. 
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METHODS 
Cloning, expression and purification 
cDNAs encoding full length Gallus gallus FANCI and FANCD2 were synthesized 
(GeneArt) and cloned into pACEBac1. The individual genes were amplified by PCR and 
cloned into pBIG1a vector using a modified version of the biGBac system, as previously 
described42,43. The combined vector was transformed into EMBacY E. coli competent cells 
for bacmid generation. The purified bacmid was then transfected into Sf9 cells. The virus was 
passaged twice before a large-scale culture was infected (5 ml of P2 virus into 500 ml of Sf9 
cells at 2 million cells/ml). Cell growth and viability were monitored and cells harvested 
upon growth arrest (typically on day 3 after infection). A similar strategy was used for 
individual expression of FANCD2 and FANCI except that the FANCD2 gene contained a C-
terminal extension with a 3C protease site and double StrepII tag whereas the FANCI gene 
contained a C-terminal extension with a 3C protease site and 6x His tag. 
For D2–I we took advantage of an excellent protein overexpression to devise a tag-free 
protein purification protocol based on sequential fractionation combining cation exchange 
and affinity chromatography. Cells were lysed by sonication in lysis buffer (100 mM HEPES 
pH 7.5, 300 mM NaCl, 1 mM TCEP, 5% glycerol, EDTA-free protease inhibitor, 5 mM 
benzamidine hydrochloride and 100 U/ml benzonase). Clarified cell lysate was passed 
through a HiTrap SP HP cation exchange chromatography column (GE Healthcare Life 
Sciences) to remove impurities. Flow-through containing the unbound D2–I complex was 
diluted to 150 mM NaCl concentration and loaded onto a HiTrap Heparin HP affinity column 
(GE Healthcare Life Sciences). Using a shallow NaCl gradient, the D2–I complex eluted 
around ~ 500 mM NaCl concentration. The complex was run on a Superdex 200 26/60 
column (GE Healthcare Life Sciences) in 50 mM HEPES pH 7.5, 150 mM NaCl and 1 mM 
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TCEP. The fractions containing the complex were pooled and concentrated to ~10 mg/ml and 
flash frozen for storage at -80 °C. Samples from each step were analyzed by SDS-PAGE 
using 4-12% NuPAGE Bis-Tris gels (ThermoFisher Scientific) to monitor the purification. 
His-tagged FANCI was purified by sequential affinity and size exclusion 
chromatography. Clarified cell lysate produced as for D2–I was loaded onto a HisTrap HP 
column (GE Healthcare Life Sciences). Using an imidazole gradient, FANCI eluted around 
~200 mM imidazole concentration. Collected fractions containing FANCI were diluted to 
~100 mM NaCl concentration and loaded onto a HiTrap Heparin HP affinity column (GE 
Healthcare Life Sciences). Using a shallow NaCl gradient, FANCI eluted around ~500 mM 
NaCl concentration. FANCI was then run on a Superdex 200 26/60 column (GE Healthcare 
Life Sciences) in 50 mM HEPES pH 7.5, 150 mM NaCl and 1 mM TCEP. The fractions 
containing FANCI were pooled and concentrated to ~10 mg/ml and flash frozen for storage at 
-80 °C. 
StrepII-tagged FANCD2 was also purified by sequential affinity and size exclusion 
chromatography. Clarified cell lysate produced as for D2–I and FANCI was incubated with 
StrepTactin Sepharose High Performance resin (GE Healthcare Life Sciences) for 60 min. 
The loaded resin was poured into a glass column and washed twice with lysis buffer before 
elution with 8 mM D-Desthiobiotin. The elution was then diluted to ~100 mM NaCl 
concentration and loaded onto a HiTrap Heparin HP affinity column (GE Healthcare Life 
Sciences). Using a shallow NaCl gradient, FANCD2 eluted around ~500 mM NaCl 
concentration. FANCD2 was then run on a Superdex 200 26/60 column (GE Healthcare Life 
Sciences) in 50 mM HEPES pH 7.5, 150 mM NaCl and 1 mM TCEP. The fractions 
containing FANCD2 were pooled, concentrated to ~10 mg/ml and flash frozen for storage at 
-80 °C. Throughout purification, we routinely monitored the absorbance at 260 nm and 280 
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nm. The A260 nm/ A280 nm ratio shows that there is no substantial nucleic acid contamination in 
the D2–I, FANCD2, or FANCI purifications. 
In vitro ubiquitination and purification of ubiquitinated D2–I 
Based on previously described ubiquitination assays8,28, we set up a large-scale in vitro 
reconstitution of the FA core complex-mediated ubiquitination of D2–I. In a total volume of 
400 µl, the reaction contained 75 nM E1 ubiquitin activating enzyme (Boston Biochem), 0.8 
µM E2 (UBE2T)8, 0.5 µM E3 (FA core complex)29, 1 µM D2–I, 5 µM DNA (double stalled 
fork generated by annealing oligonucleotides X1, X2, X3, X4, X5, X6 (Supplementary Table 
3), and 20 µM His-tagged ubiquitin (Enzo Life Sciences) in a reaction buffer of 50 mM 
HEPES pH 7.5, 64 mM NaCl, 4% glycerol, 5 mM MgCl2, 2 mM ATP and 0.5 mM DTT. The 
reaction was incubated at 30 °C for 90 min before applying it to 50 µl of Ni-NTA agarose 
resin (Qiagen) pre-equilibrated in W25 buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM 
TCEP and 25 mM imidazole) in a 1.5 ml centrifuge tube. The resin was incubated under 
constant rotation at 4 °C for 60 min. The resin was washed twice, first with 400 µl of W25 
buffer followed by a wash with 400 µl of W50 buffer (20 mM HEPES pH 7.5, 150 mM 
NaCl, 1 mM TCEP and 50 mM imidazole). Each wash was performed for 60 min at 4 °C 
under rotation. The Ni-NTA bound ubD2–I complex was eluted with W100 buffer (20 mM 
HEPES pH 7.5, 150 mM NaCl, 1 mM TCEP and 100 mM imidazole). Samples from each 
step were analyzed by SDS-PAGE to monitor the purification of ubD2–I complex. Presence 
of ubiquitin was confirmed by Western blot using anti-Ubiquitin (Millipore; Cat # 07-375). 
W100 elution fractions were then concentrated using a Vivaspin column (30 kDa MWCO) to 
a final volume of ~20 µl and ~500 nM concentration. 
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Electrophoretic mobility shift assays (EMSAs) 
Fluorescently-labeled DNA (6FAM- or Alexa647-labeled on 3ʹ end, purchased from 
IDT) was prepared by incubating complementary oligonucleotides (Supplementary Table 3) 
at 95 °C for 5 min and slowly cooling down to room temperature over ~2 h. For EMSAs, a 20 
µl reaction containing 20 nM DNA was incubated with the indicated concentration of protein 
in the presence of 50 mM HEPES pH 8.0, 150 mM NaCl and 1 mM TCEP. The reactions 
were incubated for 30 min at 22 °C. After incubation, 5 µl were directly loaded on a native 
polyacrylamide gel (6% DNA Retardation, Thermo Fisher) and run at 4 °C using 0.5 X TBE 
buffer for 60 min. The gel was then visualized using a Typhoon Imaging System (GE 
Healthcare). Each binding experiment was repeated two or three times (as indicated in figure 
legends) and ImageJ44 was used for quantification of percent DNA shifted (Fig. 4) or the 
mean intensity of free DNA and standard deviation between the measurements (Extended 
Data Fig. 4c). 
Gel filtration assays 
A volume of 300 µl of purified D2–I, FANCD2 and FANCI at 1 µM were sequentially 
run on a Superdex 200 10/300 column (GE Healthcare Life Sciences) equilibrated in 50 mM 
HEPES pH 7.5, 150 mM NaCl and 1 mM TCEP. To investigate the exchange of FANCD2 
and FANCI, we mixed and incubated 0.5 µM FANCD2 with 1 µM FANCI for 30 min at 
room temperature in a total volume of 300 µl. The mix was then run on a Superdex 200 
10/300 column (GE Healthcare Life Sciences) equilibrated in 50 mM HEPES pH 7.5, 150 
mM NaCl and 1 mM TCEP. Fractions were analyzed by SDS-PAGE using 4–12% NuPAGE 
Bis-Tris gels (ThermoFisher Scientific). 
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Protein binding assays 
We used purified StrepII-tagged FANCD2 and His-tagged FANCI to probe their 
interaction. In a total volume of 50 µl per reaction, FANCD2:FANCI at molar ratios 1:0, 
1:0.5, 1:1, 1:2, 1:5 and 0:5 were mixed in 50 mM HEPES pH 7.5, 150 mM NaCl and 1 mM 
TCEP and incubated for 15 min at room temperature. Each reaction was applied to 20 µl of 
StrepTactin Sepharose High Performance resin (GE Healthcare Life Sciences) equilibrated in 
the same buffer. The loaded resin was then incubated for 30 min at 4 °C. The unbound 
fraction was removed and the resin further washed twice using 250 µl of the same buffer. The 
bound fraction was analyzed by SDS-PAGE using 4–12% NuPAGE Bis-Tris gels 
(ThermoFisher Scientific). 
Electron microscopy and image processing 
Three microliters of ~1 µM ubD2–I, D2–I or D2 complex were blotted on plasma 
cleaned UltraAufoil R1.2/1.3 grids45 (Quantifoil) for 3–4.5 s and plunged into liquid ethane 
using a Vitrobot Mark IV. The grids were imaged on a Titan Krios using a Gatan K3 
detector. All the data collected at eBIC was in super-resolution mode and all the data 
collected at LMB was in counting mode. Additional data was collected for ubD2–I at a tilt of 
23° to overcome preferred orientation. 
All image processing was performed using Relion3.0/3.146 unless otherwise stated. The 
images were drift-corrected using MotionCorr247 and defocus was estimated using 
CTFFIND448. Particles were initially picked manually and 2D classified. Selected classes 
from the 2D classification were used to autopick particles from the full datasets. After 2–3 
rounds of 2D classification, classes with different orientations were selected for initial model 
generation in Relion. The initial model was used as reference for 3D classification into 4 
classes. The selected classes from 3D classification were subjected to auto-refinement with 
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solvent flattening using a soft mask. The defocus values were further refined using CTF 
Refinement in Relion followed by Bayesian polishing. Another round of auto-refinement was 
performed on these polished particles.  All maps were post-processed to correct for 
modulation transfer function of the detector and sharpened by applying a negative B factor as 
determined automatically by Relion. A soft mask was applied during post processing to 
generate FSC curves to yield maps of average resolutions of 3.8 Å for ubD2–I, 4.1 Å for D2–
I and 3.4 Å for D2.  
To further improve the maps, we used focused classification and refinement of the 
ubD2–I map by dividing them into FANCI, FANCD2 and DNA regions. The density for 
DNA in ubD2–I was improved by using focused classification without image alignment. 
To analyze the conformational heterogeneity in ubD2–I, we applied multi-body 
refinement using masks around FANCI and FANCD2 protomers. Two major motions were 
detected using principal component analysis on the optimal orientations of all the bodies for 
all particle images in the dataset using relion_flex_analyse49 (Supplementary Video 1). 
Modelling 
The crystal structure of Mus musculus FANDC2-FANCI (PDB: 3S4W)31 was used as a 
template to generate a homology model of Gallus gallus D2–I in I-TASSER50. The homology 
model was initially fitted manually by visual inspection of the ubD2–I, D2–I and D2 maps 
followed by rigid fitting in UCSF Chimera51. The side chains were stubbed except for K563 
of FANCD2 in ubD2–I map and the model was iteratively refined in Coot52,53 and Phenix54. 
Side chains which can be confidently identified in D2 map were added. The crystal structure 
of ubiquitin (PDB: 1UBQ)55 was rigidly fitted into the unassigned density in the ubD2–I map 
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and refined in Coot. An idealized dsDNA of 33 bp length was placed and refined in the 
density observed for DNA in ubD2–I using Coot.  
Crosslinking mass spectrometry sample preparation 
Purified ubD2–I (50 mM HEPES pH 7.5, 150 mM NaCl, 100 mM imidazole and 1 mM 
TCEP) at a concentration of ~1 µM was crosslinked with 2-fold molar ratio of 
disulfosuccinimidyl suberate (BS3) for 2 h on ice and the reaction was quenched with 50 mM 
NH4HCO3 for 30 min at room temperature. Samples were then loaded on 4–12% NuPAGE 
Bis-Tris (ThermoFisher Scientific). Gel bands of crosslinked ubD2–I complex were excised 
and digested with trypsin, as previously described56. In brief, proteins were reduced in 10 
mM dithiothreitol (Sigma Aldrich, Germany) for 30 min at 37°C and alkylated in 55 mM 
iodoacetamide (Sigma Aldrich, Germany) for 20 min at ambient temperature in the dark. 
Proteins were then digested overnight at 37°C with 10 ng μl-1 trypsin (Pierce, Germany) in 45 
mM ABC and 10% v/v acetonitrile. 
Following digestion, peptides were extracted from the gel and desalted using C18 
StageTips as described previously57. Peptides were then eluted from the StageTip using 40 μl 
80% v/v acetonitrile (ACN) in 0.1% v/v trifluoroacetic acid (TFA) into a LowBind 
Eppendorf sample tube. Solvent in the eluate was removed using vacuum centrifugation 
(Concentrator 5305 plus, Eppendorf, Germany). For LC-MS/MS analysis, peptides were re-
suspended with the sample loading buffer (0.1% v/v formic acid (FA), 1.6% v/v ACN) to a 
concentration of ~ 0.3 µg µl-1, and 3.5 μl was injected for LC-MS/MS acquisition.  
LC-MS/MS analysis 
LC-MS/MS analysis was performed using an Orbitrap FusionTM LumosTM TribridTM 
mass spectrometer (Thermo Fisher Scientific, Germany) coupled on-line to an Ultimate 3000 
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RSLCnano System (Dionex, Thermo Fisher Scientific). Peptides were separated on a 50-
centimetre EASY-Spray C18 LC column (Thermo Scientific) that is operated at 50 ºC 
column temperature. Mobile phase A consists of water, 0.1% v/v formic acid and mobile 
phase B consists of 80% v/v acetonitrile and 0.1% v/v formic acid. Peptides were loaded at a 
flowrate of 0.3 μl/min. With the same flowrate, peptides were eluted using a linear gradient 
going from 2% mobile phase B to 40% mobile phase B over 110 minutes, followed by a 
linear increase from 40% to 95% mobile phase B in eleven minutes. Eluted peptides were 
ionized by an EASY-Spray source (Thermo Scientific). 
The MS data is acquired in the data-dependent mode with the top-speed option. For 
each three-second acquisition cycle, the full scan mass spectrum was recorded in the Orbitrap 
with a resolution of 120,000. The ions with a charge state from 3+ to 7+ were isolated and 
fragmented using Higher-energy collisional dissociation (HCD). For each isolated precursor, 
one of three collision energy settings (26%, 28% or 30%) was selected for fragmentation 
using data dependent decision tree based on the m/z and charge of the precursor58. The 
fragmentation spectra were then recorded in the Orbitrap with a resolution of 50,000. 
Dynamic exclusion was enabled with single repeat count and 60-second exclusion duration. 
Identification of crosslinked peptides 
The MS2 peak lists were generated from the raw mass spectrometric data files using the 
MSConvert module in ProteoWizard (version 3.0.11729). The default parameters were 
applied, except that Top MS/MS Peaks per 100 Da was set to 20 and the de-noising function 
was enabled. The peak lists were searched against the sequences and the reversed sequences 
(as decoys) of FANCI, FANCD2, ubiquitin plus 4,514 E.coli proteins using xiSEARCH 
software (https://www.rappsilberlab.org/software/xisearch)59 for identification of crosslinked 
peptides. The following parameters were applied for the search: MS accuracy = 5 ppm; MS2 
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accuracy = 10 ppm; enzyme = trypsin (with full tryptic specificity); allowed number of 
missed cleavages = two; missing monoisotopic peak=260; crosslinker = BS3 the reaction 
specificity for BS3 was assumed to be for lysine, serine, threonine, tyrosine and protein N 
termini); fixed modifications = carbamidomethylation on cysteine; variable modifications = 
oxidation on methionine, modifications by BS3 that are hydrolyzed or amidated on the end. 
False discovery rate (FDR) was estimated based on the number of decoy identification in 
ubID2 sequences. Crosslinking mass spec data was deposited in the ProteomeXchange 
Consortium via the PRIDE61 partner repository. 
FANCD2 and FANCI structure comparisons 
The structures of FANCI and FANCD2 determined in this study were compared to each 
other and to the previously determined Mus musculus FANCI–FANCD2 structure31 using 
PDBeFOLD62. 
Reporting Summary Statement 
Further information on experimental design is available in the Nature Research 
Reporting Summary linked to this article. 
Data availability 
CryoEM maps generated during this study have been deposited in the Electron 
Microscopy Data Bank (EMDB) with accession codes EMD-10532 (D2–I), EMD-10531 
(ubD2–I), and EMD-10534 (D2–D2). Models generated during this study have been 
deposited in the protein databank (PDB) with accession codes 6TNG (D2–I), 6TNF (ubD2–I) 
and 6TNI (D2–D2). Mass spec data has been deposited in the PRIDE database with accession 
code PXD017020. Original gels and blots in Figures 1b, 4 and 5b, and Extended Data Fig. 
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1b, 3b, 3c, 4a, 4b and 5 are provided in Supplementary Fig. 1. Data for quantifications in Fig. 
4 and Extended Data Fig. 4c are available as Source Data with this paper online. 
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Supplementary Table 1. Comparison of Gallus gallus (gg) and 
Mus musculus (mm) FANCI and FANCD2 structures 
 
 Q-score/Nalign/RMSD* 
(FANCD2) 
Q-score/Nalign/RMSD* 
(FANCI) 
ggD2–I vs mmD2–I 0.22/820/3.77 0.27/848/3.16 
ggubD2–I vs mmD2–I 0.084/641/5.02 0.28/794/2.73 
ggD2 vs mmD2–I 0.25/812/3.19 n/a 
ggubD2–I vs ggD2–I 0.17/758/4.24 0.27/732/2.80 
ggubD2–I vs ggD2 0.19/785/3.91 n/a 
 
 
*Calculations were performed using PDBeFOLD (http://www.ebi.ac.uk/msd-
srv/ssm/). Q-score represents the quality function of Cɑ-alignment, maximized 
by the SSM alignment algorithm. Quality of alignment takes both the alignment 
length and root-mean squared deviation (RMSD) into account, reaching a value 
of 1 only for identical structures. Nalign is the number of matched residues, 
calculated from the best 3D superposition of query and target structures. The 
residues are aligned in 3D on the basis of their spatial closeness. The 
orientation of the structures is optimized such as to minimize RMSD and to 
maximize the number of aligned residues. Note that when there are substantial 
conformational changes, Nalign decreases (e.g. ggubD2–I vs mmD2–I).  
 
Supplementary Table 3. DNA oligonucleotides used in this study. 
 
Name Sequence (5’ to 3’) nt 
44-P1/36-FAM/ ATCGATGTCTCTAGACAGCTGCTCAGGATTGATCTGTAATGGCC/36-FAM/ 44 
39-P1/36-FAM/ ATCGATGTCTCTAGACAGCTGCTCAGGATTGATCTGTAA/36-FAM/ 39 
34-P1/36-FAM/ ATCGATGTCTCTAGACAGCTGCTCAGGATTGATC/36-FAM/ 34 
29-P1/36-FAM/ ATCGATGTCTCTAGACAGCTGCTCAGGAT/36-FAM/ 29 
24-P1/36-FAM/ ATCGATGTCTCTAGACAGCTGCTC/36-FAM/ 24 
19-P1/36-FAM/ ATCGATGTCTCTAGACAGC/36-FAM/ 19 
14-P1/36-FAM/ ATCGATGTCTCTAG/36-FAM/ 14 
10-P1/36-FAM/ ATCGATGTCT/36-FAM/ 10 
44-P1 ATCGATGTCTCTAGACAGCTGCTCAGGATTGATCTGTAATGGCC 44 
44-P7 GGCCATTACAGATCAATCCTGAGCAGCTGTCTAGAGACATCGAT 44 
39-P1 ATCGATGTCTCTAGACAGCTGCTCAGGATTGATCTGTAA 39 
39-P7 TTACAGATCAATCCTGAGCAGCTGTCTAGAGACATCGAT 39 
34-P1 ATCGATGTCTCTAGACAGCTGCTCAGGATTGATC 34 
34-P7 GATCAATCCTGAGCAGCTGTCTAGAGACATCGAT 34 
29-P1 ATCGATGTCTCTAGACAGCTGCTCAGGAT 29 
29-P7 ATCCTGAGCAGCTGTCTAGAGACATCGAT 29 
24-P1 ATCGATGTCTCTAGACAGCTGCTC 24 
24-P7 GAGCAGCTGTCTAGAGACATCGAT 24 
19-P1 ATCGATGTCTCTAGACAGC 19 
19-P7 GCTGTCTAGAGACATCGAT 19 
14-P1 ATCGATGTCTCTAG 14 
14-P7 CTAGAGACATCGAT 14 
10-P1 ATCGATGTCT 10 
10-P7 AGACATCGAT 10 
X1 GCGCACCAAGAGATACGCGGTCGAATGCCGAGTAGCCATCAGCG 44 
X2 ACCATGCAGCTACTCGGCATTCGACCGCGTATCTGGCGACTACG 44 
X3 TATCTCTTGGTGCGC 15 
X4 CGCTGATGGCTACTC 15 
X5 CGTAGTCGCCAGATA 15 
X6 GAGTAGCTGCATGGT 15 
 
1       10        20        30        40        50        6 0
ggFANCD2 M SKR        E        S       S    K        EN   F  LL  SG    V   K D  S  R  R    V   R   ILSKI AA ES KTDLQ CPETKR ISD RAPSQGGL EG EE T I
hsFANCD2 M SKR        E        S       S    K        EN   F  LL  SG    V   R E  T  K  K    I   K   ILSKS DK SL ED..A TRKQPL KTK SHIANEVE DS VK I I
mmFANCD2 M SKR        E        S       S    K        EN   F  LL  SG    I   R E  T  K  K    V   K   LRLDS DK NL ED..A T..MPL LAK SHNSHEVE GS VK A T
        70        80        90       100       110       12 0
LK GE QN   VDQ  FQ KL   L  HP YP    EF  GLES   D     NCLL C        I    A  K   K    VV   IS     Q K     V G E A T RVA E S G N HIK RS F P T
LK GE QN   VDQ  FQ KL   L  HP YP    EF  GLES   D     NCLL C        L    A  K   R    II   VS     S R     T S Q A I FQT R S K E YIE ED F S E
LK GE QN   VDQ  FQ KL   L  HP YP    EF  GLES   D     NCLL C        L    I  R   K    VI   VN     S R     T N Q G V FQA R A K E YTE SE L S E
       130       140       150       160       170       18 0
    E        Y  SLIKLLLGI ILQPA    L EK P   F        N  RLI  A  TL                VV    I F  D     VP RT GSR VHS CE K TL L E F VVGTFGT FP
    E        Y  SLIKLLLGI ILQPA    L EK P   F        N  RLI  L  SM                II    L Y  E     VR QD E.A GAS SK D KT F E F NKNSDEI IP
    E        Y  SLIKLLLGI ILQPA    L EK P   F        N  RLI  L  SM                II    V F  E     IR QD E.A GTF SK D KM F Q L SENRDGI MA
       190       200       210       220       230       24 0
 Q KWLD   D  DL    MQ  S  P   QHD ITSLPEIL DSQ   V  EL  LL   N     LL   L  ML V  I               R    F G SQ VKK S VP I E QNE A SC K Q
 Q KWLD   D  DL    MQ  S  P   QHD ITSLPEIL DSQ   V  EL  LL   S     VV   I  LI I  L               K    L R GK TTK A EN I G HAD G SD I E
 Q KWLD   D  DL    MQ  S  P   QHD ITSLPEIL DSQ   V  EL  LL   N     IV   M  LI V  L               K    L R GK TAQ A VN F G HAN G GE V Q
       250       260       270       280       290       30 0
   LTVPILD  S L LD   L K RQ  M    S  LED PV  KF LH V      E V       A       V  A V  VK     VI  I  N V   GRR L R D AEL A S TI P L KAADA
   LTVPILD  S L LD   L K RQ  M    S  LED PV  KF LH V      E V       V       V  V L  IR     II  I  S L   NTS L S R PNF L L DK S L TAMDT
   LTVPILD  S L LD   L K RQ  M    S  LED PV  KF LH V      E V       V       I  V L  VR     IV  L  S L   NTS F S R PNF S L GK S F TDTTS
       310       320       330       340       350       36 0
I  LR  L      LP     SQ KLKS   ASSS  Q      C  L FDVIK A R    D   LS V  L           S TT  V  L      V FS KS D SC LQ LG R QAQ M V SQN K L Q
I  LR  L      LP     SQ KLKS   ASSS  Q      C  L FDVIK A R    E   LQ V  L           N SS  I  L      I YS EK D HC SR QA V KGR G E GQS I S E
I  LR  L      LP     SQ KLKS   ASSS  Q      C  L FDVIK A R    E   VQ I  I           N NS  I  V      I YA EN N QF SR QA S KGL G E DKD V S E
       370       380       390       400       410       42 0
K  SEAW KAIE   S   HK  D   L  I ST     K     LR KI   C  EQL   V         V D  V  LIV L   NS NR EKV  S   M    MD I NST S L L H K QT RLG P
K  SEAW KAIE   S   HK  D   L  I ST     K     LR KI   C  EQL   I         V E  V  LVM I   NT TK DRV  N   I    LT I NTA S F F Y Q YI RSG Q
K  SEAW KAIE   S   HK  D   L  I ST     K     LR KI   C  EQL   I         A E  A  VVM I   ST TK EKL  N   I    LT F RIE A L L Y Q GV QSD Q
       430       440       450       460       470       48 0
   F  H  V KD   SIL LAQ   HS       FGS  YK AF  FD YCQQEVV A LN  Q  M I        T   VV    M      S         Q A N S FFP S FL AHPA S C Q AV C
   F  H  V KD   SIL LAQ   HS       FGS  YK AF  FD YCQQEVV A LS  S  L L        S   II    L      T         Q T V Y MCS S LL LDQS S L Y KF G
   F  H  V KD   SIL LAQ   HS       FGS  YK AF  FD YCQQEVV A LS  S  L L        T   II    L      T         D A T Y ICP L LF QDQR L L Y KF G
       490       500       510       520       530       54 0
VTH CSG E E D  LDVL  L  L  S     A FVK ILD      P QIRK F  L S   V   N  L     D VI  LL        M LN     L I   T IS T HP LRY T T S QK C Y
VTH CSG E E D  LDVL  L  L  S     A FVK ILD      P QIRK F  L S   I   N  V     E VV  AM        L IS     L V   A TA L NP MMN V G Y DN Q Y
VTH CSG E E D  LDVL  L  L  S     A FVK ILD      P QIRK F  L S   V   T  V     E IV  AM        L MS     I I   A TA L NA RLN A G Y EN Q C
        550       560       570       580       590         
TLAFS        IQDDMH VIRK LSS V   K  GIIGAVTM G  A  R             S       M       S  M        M V  NQRQE.G Y W PNH Q S LK EADGGL L
TLAFS        IQDDMH VIRK LSS V   K  GIIGAVTM G  A  R             S       L       T  I        A M  SKQNEAS H Q FKY L I AD ESPSLT Q
TLAFS        IQDDMH VIRK LSS V   K  GIIGAVTM G  A  R             N       L       T  I        A M  SQQPGTS H Q FKY L I ED VPSNSS Q
600       610       620       630       640       650         
     S E   Q   LL LV  C E  P    LYYDE ANLI   K  L    L   G   L   LST      T V             D  SERPE I CDG D GF C Q E LA L EKQ GN DLQL KF K
     S E   Q   LL LV  C E  P    LYYDE ANLI   K  L    L   G   L   VTS      S A             E  TERAN D QCT Q HS S Q Q SA F QHE .. DPKA WV H
     S E   Q   LL LV  C E  P    LYYDE ANLI   K  L    L   G   V   VTS      S A             E  TRSAN S QRT Q HS T H W SS F QER .. APKT WV Q
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
ggFANCD2
hsFANCD2
mmFANCD2
660       670       680       690       700       710         
   DF   FVVD      G F FPVK LY L E  TQ  I INLLPL             L       D         D    A      SE RVE PND LSPTV S L S N DE GA VSQ PG VAD. .
   DF   FVVD      G F FPVK LY L E  TQ  I INLLPL             I       E         E    A      QD KCN QDA SCVVP D P A G YD DG LFS FA DGGP V
   DF   FVVD      G F FPVK LY L E  TQ  I INLLPL             I       E         E    V      QE KFN QDA FCAAP D P A G YS DG FY. CA DASR A
720       730       740       750       760       770       
    S     S  CL   FRLLRL    Q  G L EID LL CP  L DLE   KL S SS  R V I          S E       LY      D L  EM N RK V P SPC YTGE NN A G T VEG
    S     S  CL   FRLLRL    Q  G L EID LL CP  L DLE   KL S SQ  K V L          N E       IF      E M  TS E GQ L P APY CVER HN G D T PGE
    S     S  CL   FRLLRL    Q  G L EID LL CP  L DLE   KL S SQ  R M L          N D       LF      E M  TS E SQ S S ASH CVAR HD G D P PGE
780       790       800       810       820       830       
   R   CSL F   NWFRE VNAFCQ    EMKGKVL RL    ELQ  L K LA  P  E L         V      Q        T  I    V    A  KQ EF L YAL Q DA QN T N G C T G
   R   CSL F   NWFRE VNAFCQ    EMKGKVL RL    ELQ  L K LA  P  E M         I      T        T  I    I    V  AK SF I LTL E SP KH V I E Y T D
   R   CSL F   NWFRE VNAFCQ    EMKGKVL RL    ELQ  L K LA  P  D M         V      T        S  L    I    V  AK SL T LTF Q SP KD V G E Y I D
840       850       860            870       880       890  
YVPP    D       P              K    K K D  K            S       T  E E  V     S E D S DPA F S AP GV SINAGGP .....R KNGK R S S ACSA RTQA E G N
YVPP    D       P              K    K K D  K            S       N  E D  A     S D E N ELG F V TL IT HTVTAIS KIRKKG IER. Q T G TSSS TLSE K C D
YVPP    D       P              K    K K D  K            S       S  D D  A     N D E T EFA V L TL MM RSSSAVA KNRNKG TGGK Q A S ASCS TLLT D C D
     900       910       920       930       940       950  
          K             L      FRELD EVFS LH GL TK ILDTEMHT ET L  A  S R Y     L    V    L           QPD ELSE E SAAEKETGNPL Q Q Y P C S
          K             L      FRELD EVFS LH GL TK ILDTEMHT ES L  L  N H F     I    I    V           PTP HRGQ N EFT.GKEEKTS L H S A C F
          K             L      FRELD EVFS LH GL TK ILDTEMHT ES V  V  N R F     I    I    V           MAP GRSH D EST.GKEGKTF S Q Y A S F
     960       970       980       990      1000      1010  
A EVVQLGP EL FLL D   KLE  LT     R    K  G    GFSHL QRS      S            D M    V  G R V  R V        EV AA C CW H P ST PFL E NKD C PK
A EVVQLGP EL FLL D   KLE  LT     R    K  G    GFSHL QRS      T            E L    M  P R V  K I        EI VP L SQ S P IA PFL N SRN Q AQ
A EVVQLGP EL FLL D   KLE  LT     R    K  G    GFSHL QRS      T            E L    M  P K I  K I        DI VA L SQ N A FA CCF N RQN H VQ
    1020      1030       1040      1050      1060      1070  
 CV  LL P CNH EN HN FQ          D      QE   M  CY  LL     L F     L   M  M  Y  V V  L I       A R   V VK K T I.PNQG V ESG N YQL SS HQ L F L
 CV  LL P CNH EN HN FQ          D      QE   M  CY  LL     L F     M   L  I  Y  L V  V V       I H   H FQ T C AAENHG V GPG K YHI SS QR Q F G
 CV  LL P CNH EN HN FQ          D      QE   M  CY  LL     L F     M   L  I  F  L A  A A       V H   H VQ T C GAEHLS D KAR T QHT AC QK Q L A
     1080      1090      1100      1110      1120      1130  
AW GF       LL SAL VL  RLK  E    PLEEL S S  YL NF  S PSFQC      S                 I       I     S QHENSN R Q AD PG TEFL E FQ L QA A F
AW GF       LL SAL VL  RLK  E    PLEEL S S  YL NF  S PSFQC      S                 L       I     S QPENQN Y H SS QG HS.Q Q VH Q HQ A L
AW GF       LL SAL VL  RLK  E    PLEEL S S  YL NF  S PSFQC      T                 V       V     K HQSKHR H E SN QM QD.Q Q FS Q HH G L
     1140       1150      1160      1170      1180      119 0
 L   LM   EK        EK ASLA Q LC  W  P G  EK    N  LH  L  Y L V  AI   R  M    K      DR     L V  I TQ S PM.TGWK F QS MK G GSHF SA T C
 L   LM   EK        EK ASLA Q LC  W  P G  EK    N  LH  L  Y L L  VI   K  I    R      DK     L I  Y IR L STASAQN F RV .. S SNIS DQ A C
 L   LM   EK        EK ASLA Q LC  W  P G  EK    N  LH  L  Y L L  AL   K  L    K      EK     V I  Y LR L SAVPNQK L RA .. H NPTF DH D Y
      1200      1210      1220      1230      1240      125 0
EHT   LKAIEEI  VGVPEL    KD  SST PTL R TF  FFRVMMA LE  VK      DNI             IN      Y   S   V         S  ISS SA GC Q P Q S S P
EHT   LKAIEEI  VGVPEL    KD  SST PTL R TF  FFRVMMA LE  VK      ESI             IN      F   T   V         T  IAG SP AS H V E K K E
EHT   LKAIEEI  VGVPEL    KD  SST PTL R TF  FFRVMMA LE  VK      DNV             VS      F   T   I         T  LTG AP AA H V E K G Q
      1260      1270      1280      1290      1300      131 0
 G   DS     EKLL WN AVR F IL NL KVFDS PVL  CLKYGR FVEAFLK  M   V       I      I  V        I              A KPS GE QL K N H R S L LA
 G   DS     EKLL WN AVR F IL NL KVFDS PVL  CLKYGR FVEAFLK  M   I       M      I  I        V              P TAA QQ HE Y D S H H L QC
 G   DS     EKLL WN AVR F IL NL KVFDS PVL  CLKYGR FVEAFLK  M   V       M      L  M        V              A TAA QQ HE Y D S Y H R QC
      1320      1330      1340      1350      1360      137 0
PLLD SF KHR DV SLL T QL TR LHH CGHSKI QD  LT HVPLLKK LE  V R      K   D             M      H           S    H Q K L S Q LG N QF Y
PLLD SF KHR DV SLL T QL TR LHH CGHSKI QD  LT HVPLLKK LE  V R      R   E             L      H           T    F L E F D L TR Q LL C
PLLD SF KHR DV SLL T QL TR LHH CGHSKI QD  LT HVPLLKK LE  V R      R   E             L      R           S    F L Q L N L TR K LL C
      1380      1390      1400      1410      1420      143 0
VKAML  N C EAFW G LKNRDLQGEEI SQ     E       E                         V               E  E AAF H Q V L ASAAP EDSA GS DTEDS AEEPDG T
VKAML  N C EAFW G LKNRDLQGEEI SQ     E       E                         L               E  D ATL N R N K NSQ.. STAD S. DMSSQ SKS... .
VKAML  N C EAFW G LKNRDLQGEEI SQ     E       E                         L               D  D VVL N R T I DPSSS SNAE S. GVTSH SRN... .
      1440      1450      1460      1470      1480      149 0
     G              D                                       DSDSG GGGHVGAGGPGAAR PPGLGQPRVHRGDHQLHQEDRRLPQLLRHVVPLPPGYA E
     G              D                                       KATED EEDEVSAGEKEQDS ESY.............DDSD.................. .
     G              D                                       RATED EDEA.SDEQKDQDS ESD.............DSSS.................. .
      1500      1510                                        
READGAGAQDRVHRGAGHQG                                        
....................                                        
....................                                        
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P
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1
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301
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895
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Supplementary Note 1. Sequence alignment of FANCD2. Sequences from Gallus gallus (gg), Homo sapiens (hs) and Mus musculus (mm) are 
shown. Under the sequence alignment, the secondary structure of ggFANCD2 is represented in blue: tubes for ɑ-helices and arrows for β-strands. For 
comparison, the helices have been labelled according to their equivalent nomenclature in the murine structure of unmodified D2–I (PDB 3S4W), and 
the solenoid (S) and helical domain (HD) numbers are indicated in light blue boxes. Red signs (“FA”) indicate mutations characterized in FA patients, 
purple signs (“P”) indicate phosphorylation sites and the monoubiquitination site K563 is marked in green (“U”). Disordered regions are marked with 
dashed lines. Sequence identities with ggFANCD2 are 56.6% for hsFANCD2 and 51.5% for mmFANCD2.
1       10        20        30        40        50        6 0
ggFANCI M   IL LA       LQE LQ L    L      QA  G     LL    KGSPCS    R  Q  E S ER      E E MVT   LR R   K I       AQ A G P A G T G GD R ETAA G F QQ S
hsFANCI M   IL LA       LQE LQ L    L      QA  G     LL    KGSPCS    K  S  E T DK      E D LLQ   VK K   R I       DQ A K A F T R G TN N VAGA A F EE A
mmFANCI M   IL LA       LQE LQ L    L      QA  G     LL    KGSPCS    K  S  D T DK      D D LLQ   VK R   R V       DL T K T F T K D AS N AVGT A L EE D
        70        80        90       100       110       12 0
G LRR   Y  C  LVESGDL     SEIIGLLMLE    PG  L  LA  F            V  VS       V          AR   A AE  T  V VIKV LQ KH HVGK QL H L E RG S
G LRR   Y  C  LVESGDL     SEIIGLLMLE    PG  L  LA  F            I  IQ       A          AH   L VE  N  I AVRT RK TC QKEI HF P E S EG S
G LRR   Y  C  LVESGDL     SEIIGLLMLE    PG  L  LA  F            I  IQ       A          VH   L VD  S  V AVRA YK SC QQDV HF P D G ED R
       130       140       150       160       170       18 0
L NGKSLEL    LTAL   KE LA GKG L GEE K QLI TLCS  W     I L           V    N         N    K       K V  N MS FST S S S Y E F N S DPQC H A
L NGKSLEL    LTAL   KE LA GKG L GEE K QLI TLCS  W     I L           I    T         S    K       R V  S MV LPI A K N Y V C N G DQQY Q T
L NGKSLEL    LTAL   KE LA GKG L GEE K QLI TLCS  W     I L           I    T         N    R       R M  S VV LPI A K V C D Y D V PQRY Q T
       190       200       210       220       230       24 0
F D  L  EE   VV K L MFSK  LQEIPPLVYQLL LS KGS   VL GII FF  L R I  S   L    V     L             L     KKT  E      P G QF E R D A S NQ
F D  L  EE   VV K L MFSK  LQEIPPLVYQLL LS KGS   VL GII FF  L K V  T   V    A     M             V     RKS  E      P A EF E S N S A SA
F D  L  EE   VV K L MFSK  LQEIPPLVYQLL LS KGS   VL GII FF  L K V  T   M    V     L             V     RRS  D      C P NL A T N S A RE
       250       260       270       280       290       30 0
DK   EEQ           T P   L HVEGT ILHIV AI LD   G EL KHLK  Q Q     EVA V       V         DI   I      RQK RVPQSADL LDQ R S N Q E TE
DK   EEQ           T P   L HVEGT ILHIV AI LD   G EL KHLK  Q Q     DVV V       I         EL   V      QHN SGDE..LL SGE R F K Y R VG
DK   EEQ           T P   L HVEGT ILHIV AI LD   G EL KHLK  Q Q     ELI A       V         EL   L      QHR SSDE..LS ADE Y F K C R AG
       310       320       330       340       350       36 0
 D    L PFS  LLLS     R   Q  D LKTS   S KDLQ LQ SKFLQ L P        V     I  E I      I R     I         K PGKA C S AVKH LQ F F T C A D C QQ Y
 D    L PFS  LLLS     R   Q  D LKTS   S KDLQ LQ SKFLQ L P        I     V  D V      V K     L         G SNNN S A TRIQ FQ L L V F G N V HR S
 D    L PFS  LLLS     R   Q  D LKTS   S KDLQ LQ SKFLQ L P        I     L  E V      V K     L         G PSKC C A TRIQ FE F L V F G T V QR T
       370       380       390       400       410       42 0
 V   ILEVV NS   WDHVTQGL   GF LM SY PKK   GK  E    LS M  Q  A T V     K  A         VD     E       A   K   D A FG L S E SFG A TNLG PA Q
 V   ILEVV NS   WDHVTQGL   GF LM SY PKK   GK  E    LS M  Q  A S M     K  V         VE     D       I   R   Y T HS L I G VLD T TSPS PN H
 V   ILEVV NS   WDHVTQGL   GF LM SY PKK   GK  E    LS M  Q  A S M     R  V         IE     D       V   K   C T HS F I G ILD A IGTS TN H
       430       440       450       460       470       48 0
CKLGA ILLETFK HE IR  ILEQVLNRV T   SP  HF DL S I   APL LQ  S     S       V    SD         L K   VS  I    VV    V  N  P AA L N S S
CKLGA ILLETFK HE IR  ILEQVLNRV T   SP  HF DL S I   APL LQ  S     N       I    QE         V R   IS  L    VM    V  S  M AS L N Y C
CKLGA ILLETFK HE IR  ILEQVLNRV T   SP  HF DL S I   APL LQ  S     N       I    QE         V R   IN  L    IM    I  N  M TS F D Y C
       490       500       510       520       530       54 0
  VTE FD L FLP  TVQ LL AVQPLLK SMS RD LILVL KA F  QLDARK AV AR      S   I      R       V   V         I          S T N D G S Q SR A
  VTE FD L FLP  TVQ LL AVQPLLK SMS RD LILVL KA F  QLDARK AV AK      S   L      K       V   M         M          S A Y Q R C R AN S
  VTE FD L FLP  TVQ LL AVQPLLK SMS RD LILVL KA F  QLDARK AV AK      T   L      K       I   M         M          . T Y Q G S R AS S
       550       560       570       580       590       60 0
GFLLLL NFK LGSL SSQC Q     QV  DVH  Y   ANE FCLEI  SL R L Q Q      R   I        S I AT  A    N A        L   R    T A G Q AC S A G C S
GFLLLL NFK LGSL SSQC Q     QV  DVH  Y   ANE FCLEI  SL R L Q Q      K   V        S L VS  V    N V        M   R    S S S H SH S T D C S
GFLLLL NFK LGSL SSQC Q     QV  DVH  Y   ANE FCLEI  SL R L Q Q      K   V        T I VT  V    S V        I   K    P S G R SR A T D S G
       610       620       630       640       650       66 0
AD RLMLY GFYDVLRRNSQLA S M TL SQ KQ Y P  DLLPPLKL  C   QG  I  V     E             S I     I  Y           IM    E L L QQ EG A DQ
AD RLMLY GFYDVLRRNSQLA S M TL SQ KQ Y P  DLLPPLKL  C   QG  I  V     E             N V     L  F           IL    Q L E KP EA T DK
AD RLMLY GFYDVLRRNSQLA S M TL SQ KQ Y P  DLLPPLKL  C   QG  I  I     D             S I     L  F           VL    Q F E EP GA T SQ
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
ggFANCI
hsFANCI
mmFANCI
       670       680       690       700       710       72 0
 LQEPL  LL CIQHCLAWYK  V         E  EE           LES T RMIK S                 S  ED    D EEM   V      F AH C T HLCKGA E EE VGFEQNF R
 LQEPL  LL CIQHCLAWYK  V         E  EE           LES T RMIK S                 N  EE    E DDI   I      S DY C T IPLQQG E .. EAFYEDL N
 LQEPL  LL CIQHCLAWYK  V         E  EE           LES T RMIK S                 S  DE    E DDM   I      F DH S R VPLQQG G .. EELYSEL V
       730       740       750       760       770       78 0
ELEDFELDKSADFS     G KNNI A   MG CEVL EYNF I  FSK  FE  L LF                SS V V     V  I    I     N   NK  DV   P G Y IQ K G G T
ELEDFELDKSADFS     G KNNI A   MG CEVL EYNF I  FSK  FE  L LF                ST I I     V  V    I     S   NR  DI   Q S C FL S S S M
ELEDFELDKSADFS     G KNNI A   MG CEVL EYNF I  FSK  FE  L LF                NT V I     I  V    M     N   SK  EI   Q N C CL S S S T
       790       800       810       820       830       84 0
CY K S IL EKAGK K         S LS  FVS LLTALFRD  QSH ESL VLRSS      E        L NR    M            NA           N L K N ST G IAR F G T E A T
CY K S IL EKAGK K         S LS  FVS LLTALFRD  QSH ESL VLRSS      D        M NK    M            SI           K L N A TK A TSD L K S Q S N
CY K S IL EKAGK K         S LS  FVS LLTALFRD  QSH ESL VLRSS      D        M SK    L            SI           K F S G AK T VSD L K D E S G
       850       860       870       880       890       90 0
EFM YAV V LQK QQL   G   GPDGQNP K FQNLC ITRVLLWRYTSIPT VEES G   R   S    V           E M                        A EEM QTD K A
EFM YAV V LQK QQL   G   GPDGQNP K FQNLC ITRVLLWRYTSIPT VEES G   R   N    V           E I                        A KET HVS D S
EFM YAV V LQK QQL   G   GPDGQNP K FQNLC ITRVLLWRYTSIPT VEES G   H   N    I           D I                        T IRT HVS D S
        910       920       930       940          950      
KK KGKSISLLCLEGL   F    Q Y     QFL ALD         E A   VT                   R  N M   RI       I D  E IN  K. L I T Q L AA P Q TDG... A D E A A
KK KGKSISLLCLEGL   F    Q Y     QFL ALD         E A   VT                   K  S V   KI       V E  D VS  RE Q I A Q F QP Q R TDKEGE R D Q T A
KK KGKSISLLCLEGL   F    Q Y     QFL ALD         E A   VT                   K  S V   KV       V E  E VT  RE Q T V L F QP Q Q MG...T E G Q A S
 960       970       980       990      1000      1010      
FQIRQFQRSL N LSS E DFNSKE  LL   L  LS LL P S QF Q L WT KICK E          V     D        I I ST  K  D    L  T       Q A TQ T G Q F V
FQIRQFQRSL N LSS E DFNSKE  LL   L  LS LL P S QF Q L WT KICK E          L     E        V V TS  K  E    V  S       L Q AL T S P M S
FQIRQFQRSL N LSS E DFNSKE  LL   L  LS LL P S QF Q L WT KICK E          L     D        I V ST  R  E    V  S       L E AL A T P M S
1020      1030      1040      1050      1060      1070      
   ED   CK L  L FSLHV YKSPV LLR L QDIH  LGDIDQDVE E   HFA V N  L    LT              E              I    I  NAL SC G L L S A AC SRS
   ED   CK L  L FSLHV YKSPV LLR L QDIH  LGDIDQDVE E   HFA V N  A    MN              D              V    I  NSR LF S L S I S GH KTN
   ED   CK L  L FSLHV YKSPV LLR L QDIH  LGDIDQDVE E   HFA V N  A    MN              D              I    V  YSQ SF S F L T S GQ KTD
1080      1090      1100      1110              1120        
  TAAPTVCLLVL QA KVLEEVDWLI                     S QA       EVK             D          RL S E  T  T L  G K TILG DT........S D SNQ QA
  TAAPTVCLLVL QA KVLEEVDWLI                     S QA       ELR             E          KL S E  S  N V  S T KGQV QETLSE..... A TLP QP
  TAAPTVCLLVL QA KVLEEVDWLI                     S QA       ELR             E          KI N D  S  T I  S A KGSA QETLSDKVTPE A VPP LL
1130      1140      1150      1160      1170      1180        
K    QLGTL T FHELVQTALP GSCVD LL  L K Y  LT     Y Q C S      VIL     L                S  R      IK  I A  T VG V A S S T AI SL H H SNT
K    QLGTL T FHELVQTALP GSCVD LL  L K Y  LT     Y Q C S      IIM     L                T  K      VR  L V  S IA F S D C M TT AL Y Q .GG
K    QLGTL T FHELVQTALP GSCVD LL  L K Y  LT     Y Q C S      IVM     V                T  K      VK  L V  S IA F S G S I ST AF Y Q .RG
1190      1200      1210      1220      1230      1240        
P   EKLVKLSGSHLTP CYSFI YVQN                     A V T MA V L L                  T     V    K  GR Q IHSESLSFAEEKKKKKKEDET S V
P   EKLVKLSGSHLTP CYSFI YVQN                     A V T MA V L M                  S     A    R  KN L KSKSLNYTG......EKKEKP A A
P   EKLVKLSGSHLTP CYSFI YVQN                     A V T MA V L V                  S     A    K  NT V KSSDAPKCS......E..KEK S T
1250      1260      1270      1280      1290      1300        
R TKPIPNL FAIEQYEKFLI LSKKSKVNLMQ MKLSTSRDF I    LD VL E     D       I                               R SM     EH Y NA S Q QNT
R TKPIPNL FAIEQYEKFLI LSKKSKVNLMQ MKLSTSRDF I    LD VL E     E       I                               K NI     DH H KG M R DGE
R TKPIPNL FAIEQYEKFLI LSKKSKVNLMQ MKLSTSRDF I    LD VL E     E       V                               K SV     DQ H KG M R DEE
1310      1320      1330                                      
  E                  EP KK R K                              D      R R A NEPDNNQSGTAEQPDENQ Q K..
  E                  EP KK R K                              E      K K N EGT......ASEHGGQNK A ...
  E                  EP KK R K                              E      R K N EGT......ASAHTQQDR A CLS
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Supplementary Note 2. Sequence alignment of FANCI. Sequences from Gallus gallus (gg), Homo sapiens (hs) and Mus musculus (mm) are shown. 
Under the sequence alignment, the secondary structure of ggFANCI is represented in red: tubes for ɑ-helices and arrows for β-strands. For 
comparison, the helices have been labelled according to their equivalent nomenclature in the murine structure of unmodified D2–I (PDB 3S4W), and 
the solenoid (S) and helical domain (HD) numbers are indicated in light red boxes. Red signs (“FA”) indicate mutations characterized in FA patients, 
purple signs (“P”) indicate phosphorylation sites and the monoubiquitination site K525 is marked in green (“U”). Disordered regions are marked with 
dashed lines. Sequence identities with ggFANCI are 66.4% for hsFANCI and 63.1% for mmFANCI.
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Supplementary Figure 1. Uncropped gels and blots
